Galderma has filed a patent for compositions and methods that stimulate the production of hyaluronic acid in the skin, improving moisture and elasticity. The patent claims a topical composition containing an octapeptide and a hexapeptide that stimulates hyaluronic acid synthesis and regulates gene expression. GlobalData’s report on Galderma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Galderma SA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Galderma, Nanoemulsion cosmetics was a key innovation area identified from patents. Galderma's grant share as of September 2023 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Topical composition for stimulating hyaluronic acid production in skin

Source: United States Patent and Trademark Office (USPTO). Credit: Galderma SA

A recently filed patent (Publication Number: US20230277429A1) describes a topical composition that aims to restore or improve the appearance of aging skin. The composition includes an octapeptide and a hexapeptide, which work together to stimulate hyaluronic acid synthesis, increase HAS2 expression, reduce HYAL2 expression, or increase EGR3 expression.

In addition to the octapeptide and hexapeptide, the composition may also contain a synthetic tripeptide, specifically tetradecyl-diaminobutyroylvalyldiaminobutyric urea trifluoroacetate. The octapeptide can have various amino acid sequences, including GDGDGASA, GPMGPSGP, GLGPGARA, GPQGFQGP, GPHGVREA, GPMGPRGP, GPGKNGDD, or GPMGPRGP. The octapeptide and hexapeptide can be encapsulated in liposomes for enhanced delivery.

The composition may further include lactoferrin, phosphatidylserine, Tremella fuciformis extract, sodium hyaluronate crosspolymer, hydroxymethoxyphenyl decanone, or a combination of these ingredients. Lactoferrin and phosphatidylserine can also be encapsulated in liposomes.

The patent also describes a method for using the topical composition to restore or improve the appearance of aging skin. The method involves administering the composition, which includes the octapeptide and hexapeptide, to stimulate hyaluronic acid production, increase HAS2 expression, reduce HYAL2 expression, or increase EGR3 expression. The composition may also include the synthetic tripeptide and can be encapsulated in liposomes.

The method can be used to improve various aspects of the skin, including hydration, the appearance of age spots, white pseudoscars, uneven skin tone, and wrinkles. It can also stimulate the production of hyaluronic acid with a molecular weight of about 2 MDa or greater. The administration of the composition can be done prior to, during, or following the injection of a filler.

Overall, this patent presents a topical composition and method for improving the appearance of aging skin by stimulating hyaluronic acid production and regulating gene expression. The composition includes peptides, liposomes, and other ingredients that work together to achieve these effects.

To know more about GlobalData’s detailed insights on Galderma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies